Comparative efficacy and safety of itraconazole, SUBA-itraconazole, and voriconazole in the treatment of recalcitrant dermatophytosis – A randomized, open label, active comparator clinical trial. - NI

I0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•1. Patients diagnosed with recalcitrant dermatophytosis (persistent disease with duration ranging 6 months to 1 year / encountered reoccurrence of the disease within = 6 weeks of completion of the treatment) of either sex between 18-70 years of age.
•2. Patient willing to participate in the study by giving informed written consent.

•1. Patients with known hypersensitivity / contraindications to azole group of drugs.
•2. Patients currently on any other antifungal medications (systemic/topical).
•3. Patients on topical corticosteroid therapy in the past two weeks.
•4. Patients on/ requiring prolonged therapy with proton pump inhibitors.
•5. Patients with pulmonary/extrapulmonary tuberculosis on treatment with anti-tubercular drug regimen involving rifampicin.
•6. Patients with concomitant therapy with carbamazepine, phenobarbitone, phenytoin.
•7. Patients on HMG-CoA Reductase Inhibitors like simvastatin, lovastatin.
•8. Patients with baseline ALT more than 3 times of upper limit of normal level.
•9. Patients on systemic immunosuppressive drugs and immunocompromised patients such as HIV positive/ post-renal transplant.
•10. Patients with known heart failure or on any drugs for cardiac arrhythmias
•11. Pregnant and lactating females.
•12. Patients with history of lactose intolerance.

发起方